RLAY
Price:
$4.34
Market Cap:
$726.44M
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology re...[Read more]
Industry
Biotechnology
IPO Date
2020-07-16
Stock Exchange
NASDAQ
Ticker
RLAY
According to Relay Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -45.75%. This represents a change of 297.41% compared to the average of -11.51% of the last 4 quarters.
The mean historical ROE of Relay Therapeutics, Inc. over the last ten years is -8.86%. The current -45.75% ROE has changed 416.39% with respect to the historical average. Over the past ten years (40 quarters), RLAY's ROE was at its highest in in the December 2019 quarter at 13.25%. The ROE was at its lowest in in the June 2021 quarter at -31.27%.
Average
-8.86%
Median
-16.59%
Minimum
-55.34%
Maximum
43.98%
Discovering the peaks and valleys of Relay Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 761.78%
Maximum Annual ROE = 43.98%
Minimum Annual Increase = -117.42%
Minimum Annual ROE = -55.34%
Year | ROE | Change |
---|---|---|
2023 | -45.47% | 69.95% |
2022 | -26.76% | -51.64% |
2021 | -55.34% | 761.78% |
2020 | -6.42% | -117.42% |
2019 | 36.86% | -16.19% |
The current ROE of Relay Therapeutics, Inc. (RLAY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-42.52%
5-year avg
-19.43%
10-year avg
-8.86%
Relay Therapeutics, Inc.’s ROE is greater than Stoke Therapeutics, Inc. (-54.45%), greater than Pliant Therapeutics, Inc. (-48.91%), greater than Black Diamond Therapeutics, Inc. (-68.08%), greater than Arvinas, Inc. (-50.26%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Mirati Therapeutics, Inc. (-40.45%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than Theseus Pharmaceuticals, Inc. (-12.35%), greater than aTyr Pharma, Inc. (-56.83%), greater than Century Therapeutics, Inc. (-66.58%), greater than Blueprint Medicines Corporation (-47.66%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Nurix Therapeutics, Inc. (-63.39%), less than Foghorn Therapeutics Inc. (167.93%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Cullinan Oncology, Inc. (-26.54%),
Company | ROE | Market cap |
---|---|---|
-54.45% | $614.95M | |
-48.91% | $811.79M | |
-68.08% | $123.92M | |
-50.26% | $1.24B | |
-22.40% | $1.28B | |
-40.45% | $4.12B | |
-85.39% | $278.99M | |
-32.76% | $503.69M | |
-103.92% | $4.13B | |
-12.35% | $181.50M | |
-56.83% | $131.12M | |
-66.58% | $86.73M | |
-47.66% | $5.74B | |
-42.45% | $286.59M | |
-62.68% | $438.66M | |
-63.39% | $1.42B | |
167.93% | $274.07M | |
-26.83% | $2.84B | |
-55.92% | $600.21M | |
-26.54% | $691.16M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Relay Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Relay Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Relay Therapeutics, Inc.'s ROE?
How is the ROE calculated for Relay Therapeutics, Inc. (RLAY)?
What is the highest ROE for Relay Therapeutics, Inc. (RLAY)?
What is the 3-year average ROE for Relay Therapeutics, Inc. (RLAY)?
What is the 5-year average ROE for Relay Therapeutics, Inc. (RLAY)?
How does the current ROE for Relay Therapeutics, Inc. (RLAY) compare to its historical average?